TY - JOUR
T1 - In-use study of potential bacterial contamination of ophthalmic moxifloxacin
AU - Mason, Ben L.
AU - Alfonso, Eduardo C.
AU - Miller, Darlene
PY - 2005/9/1
Y1 - 2005/9/1
N2 - PURPOSE: To determine the contamination rate of topical moxifloxacin 0.5% (Vigamox) after clinical use for preoperative and postoperative prophylaxis for cataract surgery. SETTING: Bascom Palmer Eye Institute, Miami, Florida, USA. METHODS: A total of 61 bottles of moxifloxacin were collected in a 2-month time period after use preoperatively by patients (n = 21, mean 2.2 days), postoperatively by patients (n = 16, mean 7.2 days), or by nurses in the operating room (n = 24). For each bottle, cultures of the cap, tip, external thread, and solution were inoculated onto chocolate agar plates and incubated at 35 degrees for 7 days. A total of 13 bottles of benzalkonium chloride (BAC)-preserved gatifloxacin ophthalmic solution (Zymar) were also cultured in a similar manner for comparison. RESULTS: No organisms were found by cultures of the cap, tip, or solution from any bottle in the study. One colony of coagulase-negative Staphylococcus was recovered from the thread of 1 Vigamox bottle. This bottle had negative cultures from its cap, tip, and solution. CONCLUSIONS: The only contaminant found in this study was cultured from the bottle thread. This is a location with a high rate of skin contact and minimal solution contact. The remaining cultures from this bottle were negative, showing the solution's ability to self-preserve. These data demonstrate that BAC-free Vigamox can be treated no differently than BAC-preserved solutions by patients and medical staff, without concern for solution contamination.
AB - PURPOSE: To determine the contamination rate of topical moxifloxacin 0.5% (Vigamox) after clinical use for preoperative and postoperative prophylaxis for cataract surgery. SETTING: Bascom Palmer Eye Institute, Miami, Florida, USA. METHODS: A total of 61 bottles of moxifloxacin were collected in a 2-month time period after use preoperatively by patients (n = 21, mean 2.2 days), postoperatively by patients (n = 16, mean 7.2 days), or by nurses in the operating room (n = 24). For each bottle, cultures of the cap, tip, external thread, and solution were inoculated onto chocolate agar plates and incubated at 35 degrees for 7 days. A total of 13 bottles of benzalkonium chloride (BAC)-preserved gatifloxacin ophthalmic solution (Zymar) were also cultured in a similar manner for comparison. RESULTS: No organisms were found by cultures of the cap, tip, or solution from any bottle in the study. One colony of coagulase-negative Staphylococcus was recovered from the thread of 1 Vigamox bottle. This bottle had negative cultures from its cap, tip, and solution. CONCLUSIONS: The only contaminant found in this study was cultured from the bottle thread. This is a location with a high rate of skin contact and minimal solution contact. The remaining cultures from this bottle were negative, showing the solution's ability to self-preserve. These data demonstrate that BAC-free Vigamox can be treated no differently than BAC-preserved solutions by patients and medical staff, without concern for solution contamination.
UR - http://www.scopus.com/inward/record.url?scp=27144549252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27144549252&partnerID=8YFLogxK
U2 - 10.1016/j.jcrs.2005.02.043
DO - 10.1016/j.jcrs.2005.02.043
M3 - Article
C2 - 16246782
AN - SCOPUS:27144549252
VL - 31
SP - 1773
EP - 1776
JO - Journal of Cataract and Refractive Surgery
JF - Journal of Cataract and Refractive Surgery
SN - 0886-3350
IS - 9
ER -